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Peripheral norepinephrine release is facilitated by presynaptic β-adrenoceptors, believed
to involve the β2-subtype exclusively. However, β1-selective blockers are the most com-
monly used β-blockers in hypertension. Here the author tested the hypothesis that β1AR
may function as presynaptic, release-facilitating auto-receptors. Since β1AR-blockers are
injected during myocardial infarction, their influence on the cardiovascular response to
acute norepinephrine release was also studied. By a newly established method, using
tyramine-stimulated release through the norepinephrine transporter (NET), presynaptic
control of catecholamine release was studied in normotensive and spontaneously hyper-
tensive rats. β1AR-selective antagonists (CGP20712A, atenolol, metoprolol) reduced norep-
inephrine overflow to plasma equally efficient as β2AR-selective (ICI-118551) and β1+2AR
(nadolol) antagonists in both strains. Neither antagonist lowered epinephrine secretion.
Atenolol, which does not cross the blood–brain barrier, reduced norepinephrine overflow
after adrenalectomy (AdrX), AdrX+ganglion blockade, losartan, or nephrectomy. Atenolol
and metoprolol reduced resting cardiac work load. During tyramine-stimulated norepineph-
rine release, they had little effect on work load, and increased the transient rise in total
peripheral vascular resistance, particularly atenolol when combined with losartan. In con-
clusion, β1AR, like β2AR, stimulated norepinephrine but not epinephrine release, indepen-
dent of adrenal catecholamines, ganglion transmission, or renal renin release/angiotensin
AT1 receptor activation. β1AR therefore functioned as a peripheral, presynaptic, facilitat-
ing auto-receptor. Like tyramine, hypoxia may induce NET-mediated release. Augmented
tyramine-induced vasoconstriction, as observed after injection of β1AR-blocker, particu-
larly atenolol combined with losartan, may hamper organ perfusion, and may have clinical
relevance in hypoxic conditions such as myocardial infarction.
Keywords: β-adrenoceptors, atenolol, metoprolol, norepinephrine release, adrenal glands, angiotensin II,
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INTRODUCTION
Beta-blockers have been first-line drugs in the treatment of hyper-
tension for half a century. The β-adrenoceptors (AR) comprise
the β1-, β2-, and β3-subtypes. Today, the β1-selective antagonist
atenolol is the beta-blocker most frequently used in hyperten-
sion and is also recommended as preventive medication after
myocardial infarction. Metoprolol, another β1AR-selective antag-
onist, which unlike atenolol crosses the blood–brain barrier, is
commonly used also during acute myocardial infarction.
Release of norepinephrine from peripheral sympathetic nerve
terminal vesicles is stimulated or inhibited by presynaptic recep-
tors (Figure 1). The first description of release-stimulating AR
was made by Adler-Graschinsky and Langer (1): β2AR but not
β1AR agonists dose-dependently increased nerve-stimulated nor-
epinephrine release, and the stimulating effect of isoproterenol on
release was blocked by β2AR but not β1AR antagonists (2–4). It has
therefore been accepted that the presynaptic, release-stimulating
βAR is of the β2-subtype exclusively. Since β2AR are by far more
effectively activated by epinephrine than norepinephrine, it has
been suggested that they are activated by circulating epinephrine,
or epinephrine co-released with norepinephrine after re-uptake
through the norepinephrine transporter (NET) (5).
However, we previously observed in whole-animal experi-
ments that not only the β2AR-selective antagonist ICI-118551 but
also the β1AR-selective antagonist CGP20712A reduced tyramine-
stimulated norepinephrine release in both spontaneously hyper-
tensive (SHR) and normotensive (WKY) rats (6). These reductions
may result from a direct effect on presynaptic β1AR, facilitating
release of norepinephrine and epinephrine. However, CPG20712A
may cross the blood–brain barrier (7), and its effect could there-
fore have resulted from a central action, thus altering sympathetic
nerve and/or adrenal release. Furthermore, intrathoracic ganglion
transmission has been shown to be facilitated by both β1AR and
β2AR (8). It is therefore possible that CPG20712A reduced norep-
inephrine overflow either directly by hampering ganglion trans-
mission, or indirectly by lowering intrathoracic ganglion trans-
mission, splanchnic nerve activation, adrenal epinephrine secre-
tion and, hence, β2AR-mediated stimulation of norepinephrine
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FIGURE 1 | Presynaptic control of norepinephrine release from peripheral
sympathetic nerve endings. Presynaptic modulation of vesicular release is
reflected as differences in overflow to plasma only when re-uptake through
NET is blocked (9). Tyramine stimulates norepinephrine release from
peripheral sympathetic nerve terminals by reverse transport through NET.
Consequently, re-uptake through NET is prevented. The influence of
presynaptic release control can therefore be studied by differences in the
tyramine-induced norepinephrine overflow to plasma (10). The presynaptic
receptors will be activated by the released transmitters, or by other agonists
present in their vicinity. The release of norepinephrine from secretory
granules is activated by adenylyl cyclase, which is stimulated and inhibited,
respectively, by stimulatory (Gs) and inhibitory (Gi) G proteins. Gs- and
Gi-activation is mediated by β1+2AR and α2AR presynaptic receptors,
respectively. The AT1R augment adenylyl cyclase activity by inhibiting
Gi-signaling. β1AR and α2AR also modulate renin release from the kidneys.
The nicotinic receptor antagonist hexamethonium will inhibit ganglion
transmission as well as nerve-stimulated epinephrine release from the
adrenals. Dotted arrows indicate nerve signals, curved arrows indicate action
of tyramine-released norepinephrine, thick arrows indicate positive effects,
whereas blunted arrows indicate inhibitory actions. Modified from Ref. (11).
release. β1AR in addition stimulate renal renin secretion (12),
which, through subsequent activation of presynaptic angiotensin
AT1 receptors (AT1R), may facilitate norepinephrine release (13).
Multiple mechanisms other than presynaptic modulation may
therefore be responsible for the CPG20712A-induced reduction
in norepinephrine release.
Norepinephrine and epinephrine have direct effects on car-
diac and vascular postsynaptic AR. Vascular β1AR may either
cause vasodilatation by activating vascular smooth muscle cell
(VSM) β1AR, or vasoconstriction by activating endothelial β1AR
and inhibiting endothelium-dependent hyperpolarization (14).
β1AR antagonists may therefore influence heart function and
organ blood flow directly, independent of their possible effects
on catecholamine release.
The purpose of the present investigation was therefore to test
the hypothesis that β1AR-mediated stimulation of norepineph-
rine release involved peripheral, presynaptic auto-receptors, or
alternatively, was due to epinephrine secretion, reduced ganglion
transmission, or reduced renal renin secretion with subsequent
presynaptic AT1R-activation. The second purpose was to study
how βAR antagonists influenced total peripheral vascular resis-
tance (TPR), cardiac function, and blood pressure (BP) at rest and
during stimulated norepinephrine release. Owing to the extensive
use of β1-selective blockers in the treatment of hypertension and
myocardia infarction, the last goal was to test if β1AR-functions
differed in WKY and SHR.
MATERIALS AND METHODS
EXPERIMENTAL PROCEDURE
Animals
All experiments were approved by The Norwegian Animal
Research Authority (NARA) and conducted in accordance with the
Directive 2010/63/EU of the European Parliament. 212 male, 12–
14 weeks old SHR (Okamoto, SHR/NHsd strain, 279± 2 g body
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weight) and 168 WKY (Wistar Kyoto, 281± 2 g body weight) on
conventional rat chow diet (0.7% NaCl) were included in the study.
Anesthesia
The rats were anesthetized with pentobarbital (65–75 mg/kg, IP).
The level of surgical anesthesia was tested by non-responsiveness to
pinching between the toes. When satisfactory anesthesia was estab-
lished, it remained throughout the experimental period without
further supply.
Surgical procedure
The rats were tracheotomized, and a heparinized catheter was
inserted into the femoral artery to record systolic (SBP) and
diastolic (DBP) BP. The rats were then connected to a positive-
pressure respirator. Entering the thoracic cavity through the third
intercostal space, a 2SB perivascular flow probe, connected to a
T206 Ultrasonic Transit-Time Flowmeter (Transonic Systems Inc.,
Ithaca, NY, USA), was placed on the ascending aorta to mea-
sure cardiac output (CO, i.e., without cardiac flow) and heart
rate (HR). The thoracic cavity was subsequently closed with a
suture, but the rats remained on the respirator and were venti-
lated with air throughout the experiment. A stabilizing period
of 10 min was allowed before the first experimental drug was
injected. Mean arterial BP (MBP= (SBP−DBP)/3+DBP), TPR
(MBP/CO), and cardiac work (SBP×HR) were calculated. Body
temperature was maintained at 37–38°C by external heating,
guided by a thermo sensor inserted inguinally into the abdom-
inal cavity. Bilateral nephrectomy (NX) or adrenalectomy (AdrX)
was performed through flank incisions. NX was done 24 h prior
to the experiment during short-time anesthesia [fentanyl citrate
(0.16 mg/kg)/fluanisone (5 mg/kg)/midazolam (2.5 mg/kg)], and
AdrX at the start of the surgical preparation for the experiment,
i.e., 30 min before injecting the first drug. The arterial catheter was
flushed with 0.15 mL buffered saline (PBS; 0.01 M Na-phosphate,
pH 7.4, 0.14 M NaCl) containing 500 IU/mL heparin. Drugs were
dissolved in PBS and administered as bolus injections through
a catheter in the femoral vein (0.6–1.0 mL/kg), unless otherwise
indicated. When the experiment was completed, the rats were
sacrificed by an IV injection of about 35 mg pentobarbital.
WORKING HYPOTHESES (FIGURE 1) AND EXPERIMENTAL PROTOCOLS
(FIGURE 2)
Protocol 1: does β1AR, like β2AR, stimulate catecholamine release?
To answer this question, the rats were pre-treated with βAR
antagonists, and 10 min later infused for 15 min with tyramine
(1.26µmol/kg/min). Tyramine stimulates norepinephrine release
from peripheral sympathetic nerve endings by activating reverse
transport through NET (15). Thus, by engaging NET in release,
re-uptake is prevented, and presynaptic modulation of vesicu-
lar release is reflected as differences in the overflow of norep-
inephrine to plasma (Figure 1), as previously documented in
detail (9, 10). The following βAR antagonists were tested: the
peripherally restricted, i.e., which does not cross the blood–
brain barrier, β1AR-selective antagonist atenolol (5.6µmol/kg),
the not restricted metoprolol (8.8µmol/kg, β1) or CGP20712A
(11µmol/kg, β1), the β2AR-selective antagonist ICI-118551 (ini-
tial dose of 1µmol/kg, followed by 0.3µmol/kg/min throughout
the experiment), or the peripherally restricted, β1+2AR antagonist
nadolol (8.5µmol/kg) (6).
Protocol 2: is the hampering effect of βAR antagonists on
norepinephrine overflow to plasma dependant on adrenal secretion
of epinephrine?
To test if the reduced norepinephrine overflow after pre-treatment
with βAR antagonists depended on secretion of epinephrine
from the adrenals, AdrX rats were pre-treated with atenolol,
CGP20712A, ICI-118551, or nadolol, followed by tyramine, as
above.
Protocol 3: does the hampering effect of β1AR antagonists on
norepinephrine overflow to plasma involve inhibition of ganglion
transmission?
In this protocol, the author tested if the β1AR antagonist-induced
reduction in norepinephrine overflow was due to aβ1AR-mediated
inhibition of ganglion transmission in AdrX rats. The rats were
therefore pre-treated with the ganglion blocker, nicotinic receptor
antagonist hexamethonium (37µmol/kg) (16), and subsequently
infused with tyramine as above. Since also not AdrX rats were
FIGURE 2 | Outline of the experimental design. During pre-treatment,
the rats were subjected to (arrows) (1) none or surgical intervention with
NX or AdrX, (2) no injection or injection of PBS or hexamethonium or
losartan, and (3) injection of PBS or βAR antagonist, in combinations as
outlined inTable 1. All rats were subsequently infused with tyramine.
Changes in MBP, CO, HR TPR, and cardiac work load (CWL) were recorded
from before drug pre-treatment to before tyramine, and every min
throughout the tyramine infusion for MBP, CO, HR, and TPR, and from
before to the end of the 15-min tyramine infusion for CWL. The effect of
NX and AdrX was analyzed by comparing the baselines prior to drug
pre-treatment with that in rats not subjected to surgical intervention.
Blood for measurement of plasma catecholamines was collected from the
femoral artery after the 15-min tyramine-observation period but without
discontinuing the infusion.
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pre-treated with hexamethonium, this protocol in addition tested
if adrenal epinephrine secretion was mediated through adrenal
nicotinic receptors.
Protocol 4: is the hampering effect of β1AR antagonists on
norepinephrine overflow due to inhibition of renal renin release
and, through that, inhibition of presynaptic, release-facilitating
angiotensin AT1 receptors?
The rats were pre-treated with the AT1R antagonist losartan
(79µmol/kg) (16), alone, or followed 10 min later by atenolol or
metoprolol, as above. Ten minutes later, all rats were infused with
tyramine. To control for a possible central effect of losartan with
subsequent reduced stress-induced sympathoadrenal activation
(17), AdrX rats were pre-treated with losartan, alone or combined
with atenolol, as above. PBS or atenolol followed by tyramine were
also given to 24-h NX rats, where a possible influence from renal
renin secretion will be eliminated.
In all protocols, control rats were pre-treated with PBS, and
included randomly throughout all protocols. Except for the WKY
and SHR control groups which comprised 13 and 16 rats, respec-
tively, each group comprised 6–9 rats (Table 1), with >6 rats
included if the intragroup variation in the catecholamine data was
large or to ensure that experiments within all four protocols over-
lapped in time. The cardiovascular analyses included data from
additional rats, where catecholamine measurements were compro-
mised or the catecholamines determined by a different method.
This concerned primarily the AdrX+PBS−, hexamethonium-
and losartan-pre-treated groups, which included 10–13 rats per
group.
MEASUREMENT OF PLASMA CATECHOLAMINES
1.5 mL blood was collected by free flow from the femoral artery
into tubes containing 45µl 0.2 M glutathione, 0.2 M EGTA (4°C).
Plasma was stored at −80°C until catecholamine concentrations
were determined using 400µl plasma and the 5000 Reagent kit for
Table 1 |The plasma concentration of norepinephrine and epinephrine.
WKY SHR
N Norepinephrine
(nM)
Epinephrine
(nM)
N Norepinephrine
(nM)
Epinephrine
(nM)
PROTOCOL 1: ROLE OF β1+2AR IN CATECHOLAMINE RELEASE
PBS+ tyramine 13 21.7±0.9 3.8±1.0 16 26.7±1.3** 5.7±0.7
Atenolol+ tyramine (peripheral β1AR ant.) 7 11.6±0.8‡‡ 2.6±0.4 8 13.8±1.1‡‡ 7.9±3.0
CGP20712A+ tyramine (β1AR ant.) 7 11.4±1.0‡‡ 2.9±0.8 7 16.7±2.4‡‡ 7.2±3.5
Metoprolol+ tyramine (β1AR ant.) 6 9.3±0.7‡‡ 1.8±0.7 6 14.6±1.2‡‡ 13.4±4.5
ICI-118551+ tyramine (β2AR ant.) 6 16.3±1.9‡ 3.2±1.5 7 15.0±1.4‡‡ 5.4±1.1
Nadolol+ tyramine (peripheral β1+2AR ant.) 7 10.2±2.5‡‡ 1.8±1.0 6 13.1±1.9‡‡ 7.4±2.9
PROTOCOL 2: ROLE OFTHEADRENALS IN β1/2AR MODULATION OF NOREPINEPHRINE RELEASE
AdrX+PBS+ tyramine 7 23.1±2.5 0.6±0.6§§ 8 31.8±3.1 0.2±0.1§§
AdrX+ atenolol+ tyramine 6 9.8±0.4‡‡ 0.0±0.0 8 23.0±2.4‡ 0.0±0.0
AdrX+CGP20712A+ tyramine 7 15.2±4.9‡ 0.0±0.0 7 22.5±2.0‡ 0.1±0.0
AdrX+ ICI-118551+ tyramine 7 15.3±1.6‡ 0.0±0.0 9 22.7±2.5‡ 0.4±0.2
AdrX+nadolol+ tyramine 8 11.6±1.9‡‡ 0.0±0.0 11 21.0±2.8‡ 0.2±0.2
PROTOCOL 3: ROLE OFADRENAL NICOTINIC RECEPTORSAND GANGLIONTRANSMISSION IN β1AR
MODULATION OF CATECHOLAMINE RELEASE
Hexamethonium+ tyramine (nicotinic receptor ant.) 6 26.1±1.4† 0.6±0.3† 6 19.6±0.9†† 1.7±0.5††
AdrX+hexamethonium+ tyramine 6 23.0±1.3 0.4±0.3 9 62.1±9.0§§ 0.6±0.4
AdrX+hexamethonium+ atenolol+ tyramine 6 12.5±0.6‡‡ 0.6±0.6 6 37.9±5.0‡ 0.6±0.6
PROTOCOL 4: ROLE OFTHE RENIN-ANGIOTENSIN SYSTEMANDTHE KIDNEYS IN β1AR MODULATION OF CATECHOLAMINE RELEASE
Losartan+ tyramine (angiotensin AT1 receptor ant.) 9a 18.4±0.7† 4.2±1.5 6a 28.4±3.4 11.8±4.1
Losartan+ atenolol+ tyramine 6 12.4±0.9‡‡ 1.4±0.2 6 17.1±1.7‡ 7.1±1.6
Losartan+metoprolol+ tyramine 6 10.5±0.5‡‡ 2.8±0.5 6 15.1±1.5‡ 11.9±2.6
AdrX+ losartan+ tyramine 7 19.3±2.0 0.2±0.1§ 12 35.6±4.7 0.2±0.0§§
AdrX+ losartan+ atenolol+ tyramine 7 13.4±0.7‡ 0.7±0.7§ 6 47.5±6.0§§ 0.0±0.0§§
NX+PBS+ tyramine 7 33.9±1.6†† 16.1±4.0† 6 34.2±2.5† 8.2±1.1
NX+ atenolol+ tyramine 6 24.6±1.4‡‡ 4.7±1.0‡ 6 25.2±2.9‡ 7.0±1.4
Comparisons were made between the SHR andWKY control groups (* after SHR values).Within each strain, comparisons were made between the PBS+ tyramine
control groups and the groups pre-treated with hexamethonium, losartan, or NX alone (†), between corresponding groups without or with pre-treatment with βAR
antagonist (‡) and corresponding groups without or with AdrX (§). Differences were detected as indicated.
N, number of rats per group. Ant., antagonist.
aFrom Ref. (11). †, ‡, § – P≤0.05, **, ††, ‡‡, §§ – P≤0.005.
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HPLC analysis of Catecholamines in plasma from Chromsystems
GmbH, Munich, Germany, as described by the manufacturer.
STATISTICAL ANALYSES
All results are presented as mean values±SE mean. Since the results
in the control groups were found to remain consistent through-
out the study, these rats were pooled into one WKY and one SHR
control group.
The plasma catecholamine concentrations were evaluated by
one-way ANOVA, first including all groups within each strain, then
including groups within each of the four protocols, or including
the controls, AdrX+PBS-, hexamethonium-, losartan-, and NX-
pre-treated groups. When the presence of group differences was
indicated, these were subsequently located by two-sample Stu-
dent’s t -tests for parametric data, and Kruskal–Wallis tests for
non-parametric results. P≤ 0.05 was considered significant.
The cardiovascular data were averaged every min. The cardio-
vascular response to pre-treatment and baselines prior to tyramine
were evaluated by one-way ANOVA, first including, within each
strain, all groups indicated in Table 2, then for sets of experiments.
When the presence of group differences was indicated, these were
subsequently located by two-sample Student’s t -tests for paramet-
ric data, and Kruskal–Wallis tests for non-parametric results. Each
step and each test employed Bonferroni-adjusted P-values.
Owing to differences in baselines, changes in the cardiovascular
responses to tyramine were presented in percentage of baselines.
The tyramine response-curves were analyzed using Repeated Mea-
sures Analyses of Variance and Covariance, first as overall tests
within each strain including all groups or sets of groups, and
subsequently between groups or for each group separately. Signif-
icant responses (one-sample Student’s t -tests) and groups differ-
ences (two-sample Student’s t - or Kruskal–Wallis tests) were sub-
sequently located at specific times, i.e., at the initial peak-pressure
response (about 3 min) and/or after 15 min. Testing proceeded
only when the presence of significant responses, differences and/or
interactions was indicated. The P-value was for all tests and each
step adjusted according to Bonferroni.
Differences in the cardiac work load in response to pre-
treatment or tyramine was analyzed by one-way ANOVA, fol-
lowed by two-sample Student’s t - or Kruskal–Wallis tests as above.
P≤ 0.05 was considered significant.
DRUGS
Losartan was a kind gift from Merck, Sharp and Dohme Labs,
Rahway, NJ, USA. ICI-118551 was obtained from ICI-Pharma,
Cheshire, UK, metoprolol tartrate from Tocris Bioscience, Bris-
tol, UK, fentanyl citrate/fluanisone (Hypnorm) from VetaPharma
Ltd., Leeds, UK and midazolam from Actavis Norway, Oslo, Nor-
way. Pentobarbital was from The Norwegian National Hospital,
Oslo, Norway. The remaining drugs were from Sigma Chemical
Co., St. Louis, MO, USA.
RESULTS
ROLE OF β1+2AR IN TYRAMINE-INDUCED NOREPINEPHRINE OVERFLOW
TO PLASMA
The tyramine-induced overflow of norepinephrine to plasma was
higher in the SHR than in the WKY controls (P= 0.003) (Table 1).
This overflow was reduced after pre-treatment with atenolol (β1),
Table 2 |The effect of pre-treatment on cardiac work load (SBP×HR) during rest and during the response to tyramine.
Pre-treatment WKY SHR
Pre-treatment (%) Tyramine 15min (%) Pre-treatment (%) Tyramine 15min (%)
PBS −4.0±3.7 168.9±17.5 −1.4±6.1 110.7±9.3
Atenolol −19.2±2.3‡‡ 129.0±5.5 −38.5±5.0‡‡ 115.0±14.1
Metoprolol −12.9±5.5 142.1±24.2 −26.1±9.1 120.5±16.8
PBS after AdrX −6.7±3.9 191.8±14.8 −13.9±3.7 84.9±14.6
Atenolol after AdrX −16.5±6.6 105.1±11.7‡‡ −34.2±2.6‡‡ 52.0±10.9
Hexamethonium −29.4±3.3†† 218.5±15.1† −50.2±6.8†† 242.4±22.8††
Hexamethonium after AdrX −17.7±1.5†† 200.6±15.1† −52.8±2.8†† 118.3±29.6
Hexamethonium+ atenolol after AdrX −25.8±6.0 140.0±10.8‡‡ −52.6±4.0 62.3±7.7
Losartana −27.8±3.1†† 158.0±16.3 −25.6±7.6 150.4±15.7
Losartan+ atenolol −29.0±5.5 163.4±14.9 −46.3±4.2‡ 166.9±22.0
Losartan+metoprolol −24.4±7.0 138.3± 8.2 −58.2±2.3‡‡ 225.7±19.7‡
Losartan after AdrX −34.1±2.9†† 167.5±11.3 −38.9±3.6†† 105.4±17.2
Losartan+ atenolol after AdrX −38.6±5.8 180.3±33.4 −54.0±3.2‡‡ 59.8±19.3
PBS after NX −21.1±5.1† 105.1±14.7† −11.6±4.2 100.2±11.9
Atenolol after NX −8.0±3.7 86.5±7.8 −10.7±3.0 67.8±8.7
The changes in cardiac work load from before to after pre-treatment were expressed in percentage of the load prior to pre-treatment, and that in response to tyramine
as change from before to that after the 15-min infusion in percentage of the before value. Comparisons were made within each strain between the PBS+ tyramine
control groups and the groups pre-treated with AdrX, hexamethonium, AdrX+hexamethonium, losartan, AdrX+ losartan or NX without β1AR antagonist (†), and
between corresponding groups without or with pre-treatment with β1AR antagonist (‡).
aFrom Ref. (11). Differences were detected as indicated. †, ‡ – P≤0.05, ††, ‡‡ – P≤0.005.
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CGP20712A (β1), metoprolol (β1), ICI-118551 (β2), and nadolol
(β1+2) in both strains. In WKY, the threeβ1AR antagonists reduced
the plasma concentration to<43% of that in the controls, whereas
the effect of the β2AR-selective ICI-118551 was less (P≤ 0.046),
i.e., reduced to 73%. A similar difference between β1- and β2AR
antagonists was not observed in SHR. The effect of the β1-
and β2AR antagonists was not additive (P=NS for the nadolol
compared to the β1 or 2AR-blocker groups).
The plasma norepinephrine concentration in AdrX rats was not
different from that in the controls, and the lowering effect of βAR
antagonists on the tyramine-induced norepinephrine overflow
remained in both strains. These results showed that β1/2AR stim-
ulation of norepinephrine release did not depend on circulating
catecholamines secreted by the adrenals during the experiment.
The nicotinic receptor antagonist and ganglion blocker
hexamethonium slightly increased the plasma norepinephrine
concentration in WKY (P= 0.028), but decreased the concentra-
tion in SHR (P< 0.001). To eliminate possible indirect effects due
to inhibition of adrenal nicotinic receptors and epinephrine secre-
tion, this experiment was repeated in AdrX rats. The effect of
hexamethonium was not different in AdrX WKY, whereas hexam-
ethonium increased overflow in AdrX SHR (P≤ 0.011 compared
to the PBS- or AdrX+PBS-pre-treated SHR groups). However,
additional pre-treatment with atenolol reduced norepinephrine
overflow in both strains (P≤ 0.039).
The AT1R antagonist losartan slightly reduced tyramine-
induced norepinephrine overflow in WKY (P= 0.011), but not in
SHR. Pre-treatment with losartan+ atenolol reduced the plasma
concentration in WKY, AdrX WKY and in SHR (P≤ 0.016 com-
pared to that after losartan alone), but not in AdrX SHR (P=NS).
Also metoprolol reduced the plasma norepinephrine concentra-
tion in losartan-treated WKY and SHR (P=NS compared to
metoprolol alone, and P≤ 0.013 compared to losartan alone).
Tyramine-induced norepinephrine overflow was higher in NX rats
of both strains (P≤ 0.015), but atenolol reduced the tyramine-
induced norepinephrine overflow also after NX (P≤ 0.037).
ROLE OF β1/2AR IN MODULATING SECRETION OF EPINEPHRINE
The plasma concentration of epinephrine in the SHR controls was
not different from that in the WKY controls (P=NS) (Table 1).
Epinephrine was almost totally absent in plasma from AdrX
rats, and was clearly reduced in hexamethonium-treated rats
(P≤ 0.009), whereas losartan had no effect. The epinephrine con-
centration was not altered after pre-treatment with βAR antag-
onists, atenolol combined with hexamethonium or losartan, or
metoprolol combined with losartan. The concentration of epi-
nephrine was higher after NX in WKY (P= 0.007) but not in SHR,
and was reduced by atenolol in NX rats of both strains (P≤ 0.022).
CARDIOVASCULAR RESPONSE TO PRE-TREATMENT
In accordance with previous studies, MBP, HR, TPR, and
cardiac work load at the start of the experiment were
higher in SHR than in WKY (96± 12 and 68± 4 mm Hg
in SHR and WKY, respectively, 415± 8 and 343± 9 bpm,
5.3± 0.3 and 2.5± 0.2 mm Hg/mL/min, and 47,049± 3335 and
28,625± 1852 mm Hg× bpm), whereas CO was less (18± 1 and
28± 2 mL/min) (P< 0.001). These parameters were clearly less
in hexamethonium-treated SHR (data not shown, Table 2 for
cardiac work load). The present analyses focused mainly on the
effect of atenolol and metoprolol. In short, atenolol reduced base-
line HR (∆HR=−37± 6 and −71± 12 bpm in WKY and SHR,
respectively,P≤ 0.004 compared to the PBS-sham-injection in the
controls) and in SHR also MBP (89± 6 mm Hg in the controls and
64± 2 mm Hg after atenolol) and CO (19± 1 in the controls and
12± 1 mL/min after atenolol) (P ≤ 0.005). Metoprolol reduced
HR in SHR only (∆HR=−65± 10 bpm, P= 0.004), but had no
significant effect on MBP. Atenolol reduced the cardiac work load
(P≤ 0.003) with a greater effect (P≤ 0.007) in SHR than in WKY,
whereas metoprolol had no effect (P=NS) (Table 2).
CARDIOVASCULAR RESPONSE TO TYRAMINE
As previously documented (11), the tyramine-induced release of
norepinephrine elicited a postsynaptic cardiovascular response,
comprising a sustained increase in MBP, CO (not shown) and HR
(Figure 3) and a transient rise in TPR (Figure 4).
The tyramine-induced tachycardia was reduced after atenolol
and metoprolol (Figures 3A,B, respectively), showing effi-
cient inhibition of cardiac, postsynaptic β1AR. The metoprolol-
induced reduction in the tachycardia was eliminated in
losartan-pre-treated SHR. Tyramine increased cardiac work load,
and with a greater effect in WKY than SHR (Table 2). This increase
was not significantly reduced by atenolol or metoprolol, alone or
combined with losartan.
The losartan-dependant reduction in the TPR-response to tyra-
mine, which was observed in WKY only, was further enhanced
by AdrX (P≤ 0.014), and a reduced ∆TPR was seen also in
AdrX+ losartan-pre-treated SHR (Figure 4A). Atenolol greatly
increased the TPR-response in losartan-treated rats of both strains,
also after AdrX (P≤ 0.008), particularly in WKY (Figure 4A). Sim-
ilar to that observed in losartan-treated rats, the late TPR-response
to tyramine was reduced after NX in WKY only (P< 0.001), and
this reduction was eliminated by atenolol (P= 0.002) (Figure 4B).
Metoprolol alone increased the TPR-response to tyramine in WKY
(P≤ 0.007), particularly the early peak-response (Figure 4C).
Pre-treatment with losartan+metoprolol elevated the late TPR-
response in both strains (P≤ 0.024 compared to the controls)
(Figure 4C).
DISCUSSION
The main observation in the present study was that the β1AR sub-
type, like β2AR, functioned as a presynaptic, auto-receptor, and
stimulated norepinephrine release from peripheral sympathetic
nerves. However, neither β1- nor β2AR influenced the secretion
of epinephrine. In addition, atenolol combined with losartan
greatly increased the rise in TPR in response to endogenous
norepinephrine release.
USE OF TYRAMINE TO STUDY PRESYNAPTIC MODULATION OF
NOREPINEPHRINE RELEASE IN VIVO
Norepinephrine overflow to plasma is normally low due to synap-
tic re-uptake through NET (Figure 1), and presynaptic control
of basal release from presynaptic vesicles has little influence on
the plasma norepinephrine concentration in the anesthetized rat
(9). Indeed, the β1+2AR antagonist nadolol did not alter norep-
inephrine overflow to plasma even during stimulated, vesicular
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FIGURE 3 |The effect of atenolol (A) or metoprolol (B) on the
HR-response to tyramine inWKY and SHR. The rats were pre-treated as
outlined in the legends. After overall and step-by-step curve evaluations
with Repeated Measures Analyses of Variance and Covariance (please see
Statistical Analyses), group differences were located at 15 min (* in brackets
right of curves), as indicated. Comparisons were made in (A) between the
controls and losartan-treated groups, between the losartan- and
AdrX+ losartan-pre-treated groups and between corresponding groups
without and with pre-treatment with atenolol; and in (B) between the
controls and the metoprolol-treated groups, and between the metoprolol-
and the losartan+metoprolol-treated groups. In the same order as in the
legends, HR baselines prior to tyramine was in (A) 340±9, 338±9,
333±13, 312±10, 310±8, 304±10, 307±16 bpm in WKY and 394±5,
360±10†, 343±13†, 325±9†, 372±6†, 328±21†, 297±5† bpm in SHR
(†; P≤0.0083 compared to the controls), and in (B) 340±9, 300±8†,
318±14 bpm in WKY and 394± 5, 333± 12†, 292±7† bpm in SHR
(†P≤0.004). * In brackets – P≤0.05 after curve evaluations with
Bonferroni-adjusted P -values.
norepinephrine release, sufficient to cause a maximum increase in
HR (18). However, when re-uptake through NET was blocked by
desipramine, the inhibiting effect of presynaptic α2AR on release
(Figure 1) could be demonstrated by an α2AR antagonist as an
increase in norepinephrine overflow, even without stimulation of
release (9). Reversed transport of norepinephrine through NET
can be stimulated by tyramine (Figure 1). This transport is not
under presynaptic control (19). However, by engaging NET in
release, tyramine prevents re-uptake, and also supplies norepi-
nephrine as agonist for presynaptic facilitation and inhibition of
a concomitant vesicular release. Presynaptic stimulation and inhi-
bition of vesicular release is therefore reflected as differences in
the tyramine-induced norepinephrine overflow to plasma (6, 10,
11). The questions posed in the present investigation, involved
several organs, and could therefore be answered only through
experiments on intact animals. Tyramine-induced norepinephrine
overflow to plasma provided a method to study how other organs
FIGURE 4 |The effect of atenolol (A, B) or metoprolol (C) on the
TPR-response to tyramine inWKY and SHR. The rats were pre-treated as
outlined in the legends. After overall and step-by-step curve evaluations
with Repeated Measures Analyses of Variance and Covariance (please see
Statistical Analyses), significant responses were located at peak-response
(all significant except in the WKY AdrX+ losartan+ tyramine group, not
indicated) and at 15 min (* within symbol, as indicated). Group differences
were located at the same times (* in brackets left and right of curves,
respectively), as indicated. Comparisons were made in (A) between the
PBS- and losartan-treated groups in not AdrX and AdrX rats, between the
losartan- and AdrX+ losartan-pre-treated groups, and between
corresponding groups without and with pre-treatment with atenolol; in
(B) between the controls and the NX groups, between corresponding
groups without and with pre-treatment with atenolol; and in (C) between
the controls and the metoprolol-treated groups, and between the
metoprolol- and the losartan+metoprolol-treated groups. In the same
order as in the legends, TPR baselines prior to tyramine was in mm
Hg/mL/min in (A) 2.1±0.1, 1.7±0.1, 1.7±0.1, 2.2±0.1, 2.3±0.2,
2.2± 0.2 in WKY and 4.8±0.2, 4.0±0.5, 4.1±0.4, 6.3±0.5, 7.6±1.1,
5.1± 0.9 in SHR, in (B) 2.1±0.1, 2.4±0.1, 1.4± 0.1†, 1.9±0.2 in WKY and
4.8± 0.2, 5.7±0.4, 2.2±0.3†, 4.1±0.5 in SHR, and in (C) 2.1±0.1,
2.0±0.2, 1.6± 0.1† in WKY and 4.8±0.2, 4.3±0.2, 4.1±0.3 in SHR
(†P≤Bonferroni-adjusted P -values). * In brackets – P≤0.025 after curve
evaluations with Bonferroni-adjusted P -values.
and systems may contribute to the control of norepinephrine
release.
DEMONSTRATION OF β1AR AS A PRESYNAPTIC AUTO-RECEPTOR,
FACILITATING THE RELEASE OF NOREPINEPHRINE
The present results clearly demonstrated that not only the
β2AR-selective antagonist ICI-118551, but also the β1AR-selective
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antagonists CGP20712A, atenolol and metoprolol lowered
tyramine-induced norepinephrine overflow. Since tyramine and
atenolol do not readily cross the blood–brain barrier, it was con-
cluded that the β1AR involved was peripherally located. The effect
of the β1AR antagonists was slightly greater than that of the β2AR
antagonist in WKY, but not in SHR. However, inhibition of both
β1- and β2AR did not lower overflow more than β1- or β2AR
antagonist alone in either strain. This result demonstrated that
the effect of the two βAR was not additive, compatible with a
common signaling pathway for both receptors, i.e., activation of
adenylyl cyclase (Figure 1).
The catecholamine responsible for the β1- and β2AR-mediated
stimulation of norepinephrine release did not rely on cate-
cholamines secreted from the adrenals during the experiment.
This was concluded from the fact that β1- or β2AR antagonist
reduced tyramine-induced norepinephrine overflow also in AdrX
rats. However, the adrenals were removed only 30 min prior to
administration of antagonist. Epinephrine, previously taken up
from the circulation through NET, may therefore still be present
in the nerve terminal vesicles and co-released with norepinephrine
(5). Since the affinity of the β2AR is much higher for epinephrine
than norepinephrine, it could not be excluded that this epineph-
rine activated presynaptic β2AR. On the other hand, the affinity
of the β1AR for norepinephrine and epinephrine does not dif-
fer. It was therefore concluded that norepinephrine, released by
tyramine from peripheral nerves, activated the peripheral β1AR
which facilitated norepinephrine release. Atenolol in addition
reduced tyramine-induced norepinephrine overflow after pre-
treatment with AdrX+ hexamethonium in both strains. Thus,
the reduced overflow of norepinephrine after pre-treatment with
atenolol also did not involve a central nervous system component
or β1AR-mediated stimulation of ganglion transmission.
The slightly reduced tyramine-induced norepinephrine over-
flow after losartan in WKY was likely to result from inhibition
of presynaptic AT1R, which stimulate release (13, 20). However,
losartan did not eliminate the hampering effect of atenolol or
metoprolol on norepinephrine overflow in WKY or SHR, and
atenolol reduced tyramine-induced norepinephrine overflow also
in 24-h NX rats. It was therefore concluded that the stimulat-
ing effect of β1AR on norepinephrine release was not mediated
through activation of renal renin secretion (21), with subsequent
activation of presynaptic, release-stimulating AT1R (Figure 1).
Atenolol reduced norepinephrine release also in AdrX+ losartan-
pre-treated WKY. AT1R-mediated stimulation of adrenal cate-
cholamines (22) was therefore not involved. However, atenolol
did not lower norepinephrine overflow in AdrX+ losartan-pre-
treated SHR. This observation may possibly be explained by
the fact that AT1R antagonist restored α2AR-mediated inhibi-
tion of norepinephrine release in this strain (11). A losartan-
dependent, enhanced α2AR-mediated inhibition of release may
therefore possibly counter-act the effect of β1AR-mediated stimu-
lation and, hence, the effect of atenolol, when also a substituting,
β2AR-mediated stimulation of release was eliminated by AdrX
(Figure 1).
Hexamethonium itself reduced tyramine-induced norepineph-
rine overflow in SHR, possibly explained by inhibition of
presynaptic, nicotinic receptors, which stimulated vesicular release
(23). But it may also result from inhibition of ganglion trans-
mission, which will lower the sympathetic nerve tone, which is
responsible for the vesicular release. The latter possibility was
supported by that hexamethonium reduced MBP, HR, TPR, and
cardiac work load with a greater effect in SHR than in WKY.
However, in WKY, and even more in AdrX SHR, hexamethonium
enhanced norepinephrine overflow. The mechanism underlying
this observation was not clarified by the present experiments.
From these experiments, it was concluded thatβ1AR functioned
as a presynaptic auto-receptor in peripheral sympathetic nerves
and stimulated norepinephrine release. This conclusion differed
from that previously observed in nerve-stimulated rat portal veins
and human arteries and veins where β2AR alone enhanced nor-
epinephrine release (3, 4, 24). However, both subtypes enhanced
electrically stimulated norepinephrine release in rat brain slices
and canine intrathoracic ganglia (8, 25), and β1AR mRNA and
protein have been detected in rat sympathetic neuronal cell bodies
and axons (26). The present results were also fully compatible with
the increased ventricular sympathetic axon proliferation in rats
given a 1-week treatment with metoprolol (26), possibly to com-
pensate for a reduced norepinephrine release. Tyramine selectively
stimulates norepinephrine release through NET, whereas electri-
cal stimulation elicits release from the nerve terminal vesicles,
which may contain also other transmitters, including epinephrine.
Since presynaptic control of release regulates vesicular release only
(19), β1AR-inhibition will lead to a down-regulation of release
of transmitters other than norepinephrine, while still permit-
ting NET-mediated norepinephrine release. The present exclusive
release of norepinephrine stimulated by tyramine may therefore
favor the demonstration of the facilitating β1AR.
CONTROL OF ADRENAL EPINEPHRINE SECRETION
Tyramine did not evoke secretion of epinephrine, and the elevated
plasma concentration was due to the stress-induced by the surgery
(9, 10). This was as expected, since adrenal cortical glucocorticoid
release with subsequent epinephrine secretion may respond to any
type of stress, including surgery, and is not, like norepinephrine
release from the adrenal and most sympathetic nerves, regulated
by the baroreceptor reflex. Epinephrine secretion is mediated
through nicotinic receptors on adrenal chromaffin cells (27); in
accordance with the observed clear reduction after pre-treatment
with the nicotinic receptor antagonist hexamethonium in both
strains. The plasma epinephrine concentration was not reduced
after any of the βAR antagonists in either strain, in spite of that
inhibition of the α2AAR increased epinephrine secretion in sim-
ilar experiments (9). Although losartan through a central action
may lower stress-induced sympathoadrenal activation (17), losar-
tan did not alter the concentration of epinephrine. However, the
plasma epinephrine concentration was higher in 24-h NX WKY
but not SHR. It may be speculated that this increase resulted from
removal of afferent renal nerve signaling, which lowers sympa-
thetic output, at least to the kidney (28). This reflex was reduced in
SHR (29). The mechanism may involve peripheral β1AR, since the
increased epinephrine concentration in NX WKY was eliminated
by atenolol.
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IMPLICATIONS OF PRESYNAPTIC, STIMULATING β1AR IN THE
TREATMENT OF HYPERTENSION
Atenolol is the most commonly used β1AR-blocker in the treat-
ment of hypertension. Hypertensive disease is in most patients
due to increased sympathetic nerve activity (30). This is likely
to be due to an increased central sympathetic output, since cloni-
dine reduced resting norepinephrine overflow, MBP, HR, and TPR
through a central action in SHR but not WKY (9). The present
results indicated that the antihypertensive effect of β1AR-selective
antagonists may be explained by their ability to hamper norepi-
nephrine release through presynaptic modulation, in agreement
with previous analyses showing that the hypotensive effect of AR
antagonists, including atenolol, did not depend on cardio depres-
sion or suppression of renin secretion (31). Sympathetic nerve
activation is also seen in heart failure and myocardial infarc-
tion, first compensating for the failing function, but eventually
it has a detrimental effect, causing receptor desensitization due
to long-term exposure to increased levels of norepinephrine. The
beneficial therapeutic effect of β1AR-selective antagonists in such
cardiac conditions may therefore include also their ability to lower
norepinephrine release.
The two β1AR-selective antagonists atenolol and metoprolol,
when injected IV, reduced resting HR but had little effect on TPR,
and only atenolol caused a minor reduction in MBP and in SHR
only, due to a reduction in CO. Since the ganglion blocker hexa-
methonium reduced all cardiovascular parameters in this strain,
including TPR, the acute effect of the β1AR antagonists was pri-
marily cardio-selective and due to postsynaptic intervention. As
expected from the elevated sympathetic tone in SHR, atenolol and
metoprolol reduced resting HR, and atenolol, but not metopro-
lol, lowered resting cardiac work load with a greater effect in SHR
than in WKY. A reduced work load was seen also after losartan,
with a further reduction after addition of atenolol or metoprolol
in SHR only. These effects were compatible with reduced cardiac
energy consumption, which is a therapeutic goal in heart failure
and myocardial infarction.
POSSIBLE CARDIOVASCULAR COMPLICATIONS RESULTING FROM THE
USE OF β1AR ANTAGONISTS
The tyramine-induced tachycardia was not prevented by meto-
prolol when combined with losartan in SHR, and atenolol and
metoprolol, alone or combined with losartan, had little effect
on the tyramine-stimulated rise in cardiac work load in either
strain. The transient rise in TPR during tyramine-induced nor-
epinephrine release was, as previously described (11), changed
to vasodilatation during the late part of the tyramine infusion in
losartan-treated WKY but not in SHR. This observation indicated,
as expected, that angiotensin II-AT1R-activity may potentiate
norepinephrine-induced vasoconstriction. The same pattern was
observed in NX rats, indicating that the angiotensin II-formation
depended on renin released from the kidneys. Furthermore, after
AdrX+ losartan, the TPR-peak-response was eliminated in WKY,
and was reduced throughout the tyramine infusion-period in
SHR. These observations were not explained by differences in
norepinephrine release, and apparently indicated increased post-
synaptic, adrenal catecholamine-dependent control of vascular
tension in the absence of AT1R-activity. However, in the presence
of losartan, atenolol greatly enhanced the TPR- and MBP-response
to tyramine, particularly in WKY and also in AdrX rats of both
strains. It therefore appeared that VSMC β1AR-mediated vasodi-
latation played a crucial role in antagonizing AT1R-mediated
vasoconstriction. This pattern differed from that observed after
pre-treatment with metoprolol. Metoprolol increased the TPR-
peak-response to tyramine in WKY, but not when combined with
losartan, whereas metoprolol increased the late TPR-response in
SHR only if combined with losartan. This difference may be due
to that metoprolol, unlike atenolol, readily crosses the blood–
brain barrier. These observations may be of great clinical impor-
tance. Norepinephrine is normally released from nerve terminal
vesicles in response to sympathetic nerve action potentials, and
is lowered through presynaptic receptors by the β1AR antago-
nists. However, myocardial ischemia lasting more than 10 min
will cause nerve terminal ATP depletion, hypoxia, and a fall in
intracellular pH, leading to massive, reverse transport through
NET, with extracellular catecholamine accumulation up to 100–
1000 times greater than that in plasma (32). Thus, during local
or global cardiac ischemia, the condition will be comparable to
that induced by tyramine-stimulation, and inhibition of β1AR-
mediated vasodilatation may disturb cardiac perfusion, particu-
larly if combined with losartan, without having the desired effect
on cardiac work load and cardiac energy consumption. This may
explain why vasodilatory β-blockers reduced overall mortality
with a greater effect than non-vasodilatory β-blockers such as
atenolol (33).
CONCLUSION
Peripheral β1AR, like β2AR, were for the first time demonstrated
in vivo to function as a presynaptic, auto-receptor, facilitating
release of norepinephrine from peripheral sympathetic nerves
in WKY and SHR. Inhibition of norepinephrine release may
therefore explain the antihypertensive effect of β1AR-selective
antagonists such as atenolol, the most frequently used β-blocker
in the treatment of hypertension. The reduced norepinephrine
release may be beneficial also in other conditions with sympa-
thetic hyperactivity such as heart failure and myocardial infarction
in addition to the sparing effect of β1-blockers on cardiac work
load and energy consumption. However, when massive norepi-
nephrine release was precipitated by reverse transport through
NET, as by tyramine in the present study, but which may be
induced by hypoxia during myocardial infarction and ischemic
heart disease, the sparing effect of the β-blockers on cardiac
work load was limited. In addition, inhibition of postsynaptic,
β1AR-mediated vasodilatation greatly increased norepinephrine-
induced vasoconstriction. This response may hamper organ per-
fusion, and aggravate the condition they are meant to prevent.
This reaction was particularly pronounced when atenolol was
combined with losartan, a commonly used drug combination
in the clinic. The role of reversed NET transport of norepi-
nephrine in cardiovascular events may therefore deserve more
attention.
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